van der Kolk, L E <br/><br/>
Complement activation plays a key role in the side-effects of rituximab treatment.  [electronic resource] 

 -  British journal of haematology  Dec 2001 
 - 807-11 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0007-1048 
<br/><br/><label>Standard No.: </label>10.1046/j.1365-2141.2001.03166.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Agents--adverse effects<br/>Complement Activation<br/>Complement C3b--analysis<br/>Complement C3c--analysis<br/>Complement C4--analysis<br/>Complement C4b--analysis<br/>Cytokines--blood<br/>Female<br/>Humans<br/>Interleukin-6--blood<br/>Interleukin-8--blood<br/>Lymphocyte Count<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Middle Aged<br/>Peptide Fragments<br/>Rituximab<br/>Stimulation, Chemical<br/>Tumor Necrosis Factor-alpha--analysis